Head-to-head evidence
Blixeprodil vs Esketamine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: NMDA receptor · full Major Depressive Disorder pipeline
Blixeprodil
Developed by Gilgamesh Pharmaceuticals
NCT06309277 · Phase 2 · completed
The study was randomized, quadruple-blind, placebo-controlled, and included 46 participants, but the primary endpoint was treatment-emergent adverse-event incidence rather than an efficacy endpoint. The registry reports adverse-event counts but no statistical comparison for this primary endpoint, so whether it was met is unclear; the depression-rating result was a statistically significant secondary finding.
Esketamine · Spravato
Marketed by Johnson & Johnson
NCT02417064 · Phase 3 · completed
The study randomized 346 participants to double-blind 56 mg esketamine, 84 mg esketamine, or matching placebo, each with an oral antidepressant, and used the clinical MADRS depression score as its primary endpoint. The 56 mg dose significantly outperformed placebo, while the 84 mg dose did not, so the primary results were mixed despite the strong trial design.
Next expected readout: December 2026 · NCT07369102 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Blixeprodil's landscape · Esketamine's landscape